Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multisystemic Therapy-Emerging Adults (MST-EA) for Substance Abuse

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03035877
Recruitment Status : Recruiting
First Posted : January 30, 2017
Last Update Posted : March 13, 2019
Sponsor:
Collaborator:
University of Massachusetts, Worcester
Information provided by (Responsible Party):
Ashli Sheidow, Oregon Social Learning Center

Brief Summary:
This study's purpose is to examine the effectiveness of a promising intervention for emerging adults (EAs) with alcohol and other drug (AOD) abuse and justice involvement in achieving the ultimate outcome of reduced criminal activity. The study will also examine that effect on intermediate outcomes as follows: 1) reduced AOD use; 2) greater gainful activity (increased educational success, employment and housing stability; decreased antisocial peer involvement and relationship conflict); 3) and greater improvement in self-regulation (self-efficacy, goal directedness and responsibility taking). The intervention to be tested is Multisystemic Therapy-Emerging Adults (MST-EA). MST-EA is an adaptation of MST, a well-established, effective intervention for antisocial behavior in adolescents.

Condition or disease Intervention/treatment Phase
Antisocial Behavior Behavioral: Multisystemic Therapy-Emerging Adults Behavioral: Enhanced Treatment as Usual Not Applicable

Detailed Description:

Prevalence of alcohol and other drug (AOD) abuse and criminal activity is highest during emerging adulthood compared to any other developmental period, and causes extraordinary costs to society. Emerging Adults (EAs; ages 17-21) with AOD abuse have greater incarceration rates than EAs without AOD abuse, and AOD-abusing offenders have significantly more recidivism, severe offending, and incarceration than other offenders. Such serious behavior interferes with successful transition into adulthood in areas such as school completion, employment and housing. Thus, there is a strong public health need for effective treatment to reduce AOD abuse and justice involvement in EAs. Surprisingly, there are no interventions with established efficacy to reduce criminal activity among EAs, with or without AOD abuse. Among younger adolescents, the comprehensive causes of antisocial behavior are addressed by effective interventions (e.g., Multisystemic Therapy [MST]; Treatment Foster Care Oregon [TFCO]), and the present investigative team has developed and evaluated a well-defined age-tailored intervention for EAs with criminal behavior. The developed intervention is an adaptation of MST and integrates a skills coaching component from TFCO, both well-established effective juvenile justice interventions. Initial MST-EA research focused on justice-involved young adults who had mental health problems, a high-risk subpopulation of offenders, but AOD abuse quickly became a primary problem the MST-EA team treated. As a single-source intervention, MST-EA targets the EA correlates of criminal activity and AOD abuse, including gainful EA activities (positive relationships, school, work, and housing) and reduced AOD abuse—in part by targeting the proximal mechanism of poor self-regulation. In a successfully completed community-based open trial, the safety, feasibility, and preliminary efficacy of the intervention were established.

The proposed study will evaluate the effectiveness of MST-EA for reducing justice involvement and AOD abuse. EAs (n = 240) with AOD abuse and justice involvement (recent arrests or release from justice facilities) will be randomized to receive MST-EA or Enhanced Treatment as Usual (E-TAU). Assessments will be completed at months 0, 2, 4, 6, 8, 12, and 16, with confirmation of outcome data using collateral reports and official records. Aims will be to evaluate the effect over time of MST-EA for reducing AOD abuse and criminal activity, as well as to evaluate the effect of MST-EA on the key proximal target of treatment (self-regulation) and intermediate outcomes of treatment (gainful activities). A final aim of the study will be to investigate if the direct effect of treatment on criminal activity is mediated by its effect on self-regulation, AOD abuse, and gainful activities. In this specific age group, there is a complete absence of AOD abuse and recidivism reduction treatments with demonstrated effectiveness. The ultimate effect of the proposed research would be decreased AOD abuse and justice involvement in a high-risk population, as well as improved outcomes that have significant societal impact (e.g., reduced homelessness and unemployment).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Treatment of Justice-Involved Emerging Adults With Substance Use Disorders
Actual Study Start Date : August 28, 2017
Estimated Primary Completion Date : January 15, 2021
Estimated Study Completion Date : April 15, 2021

Arm Intervention/treatment
Experimental: Multisystemic Therapy-Emerging Adults
This group will receive Multisystemic Therapy-Emerging Adults.
Behavioral: Multisystemic Therapy-Emerging Adults
MST-EA is a home- and community-based treatment for emerging adults (ages 17-21) that aims to address antisocial behavior and problems caused by substance use disorders. The model also addresses co-occurring mental health problems when present. Therapists work directly with the young adult and his/her social network. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
Other Name: MST-EA

Active Comparator: Enhanced Treatment as Usual
This group will have access to an enhanced version of services typically delivered to young adults who have a substance use disorder and have been in trouble with the law.
Behavioral: Enhanced Treatment as Usual
With Enhanced Treatment as Usual (E-TAU), emerging adults will get the treatments that they usually receive when they have a substance use disorder and have been in trouble with the law. In addition, they will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
Other Name: E-TAU




Primary Outcome Measures :
  1. Change in number and severity of criminal charges in official records in the 16 months pre-Baseline compared with the 16 months post-Baseline. [ Time Frame: 16 months pre-Baseline compared with 16 months post-Baseline. ]
    Changes from the 16 months pre-Baseline in offending as measured by the number and severity of criminal charges in official records compared to 16 months post-Baseline.

  2. Changes from Baseline scores compared to 16 months post-Baseline Offending Behaviors (measured at 0, 2, 4, 6, 8, 12 and 16 months). [ Time Frame: Baseline to 16 months. ]
    Offending behaviors as measured using the Self-Report Offending Scale (self- and collateral reports).


Secondary Outcome Measures :
  1. Changes from Baseline scores compared to 16 months post-Baseline Self-efficacy (measured at 0, 2, 4, 6, 8, 12 and 16 months). [ Time Frame: Baseline to 16 months. ]
    Self-efficacy as measured using the Self-Efficacy Scale (self- and collateral reports).

  2. Changes from Baseline scores compared to 16 months post-Baseline Goal Directedness (measured at 0, 2, 4, 6, 8, 12 and 16 months). [ Time Frame: Baseline to 16 months. ]
    Goal directedness measured using the Wills Self Control Measure (self- and collateral reports).

  3. Changes from Baseline scores compared to 16 months post-Baseline Responsibility Taking (measured at 0, 2, 4, 6, 8, 12 and 16 months). [ Time Frame: Baseline to 16 months. ]
    Responsibility taking measured using the Behavioral Indicators of Conscientiousness (self- and collateral reports).

  4. Changes from Baseline scores compared to 16 months post-Baseline Urine Drug/Alcohol Screens (measured at 0, 2, 4, 6, 8, 12 and 16 months). [ Time Frame: Baseline to 16 months. ]
    The number of positive urine screens for tetrahydrocannabinol (THC), synthetic THC, amphetamines, methamphetamines, phencyclidine (PCP), opiates, benzodiazepines, cocaine, and specific metabolites of alcohol (Ethyl glucuronide, Ethyl sulfate).

  5. Changes from Baseline scores compared to 16 months post-Baseline Treatment Usage (measured at 0, 2, 4, 6, 8, 12 and 16 months). [ Time Frame: Baseline to 16 months. ]
    The number of hospitalizations, emergency room visits and other treatments for alcohol or drug use as measured using the Time Line Follow Back (self-report) and from archival records.

  6. Changes from Baseline scores compared to 16 months post-Baseline Substance Use and Problems (measured at 0, 2, 4, 6, 8, 12 and 16 months). [ Time Frame: Baseline to 16 months. ]
    Frequency of substance use and substance-related problems as measured by the Global Appraisal of Individual Needs (self- and collateral reports).

  7. Changes from Baseline scores compared to 16 months post-Baseline Antisocial Peers Involvement (measured at 0, 2, 4, 6, 8, 12 and 16 months). [ Time Frame: Baseline to 16 months. ]
    Antisocial peer involvement measured using the Peer Delinquency Scale (self- and collateral reports).

  8. Changes from Baseline scores compared to 16 months post-Baseline Interpersonal Competence (measured at 0, 2, 4, 6, 8, 12 and 16 months). [ Time Frame: Baseline to 16 months. ]
    Social conflict and social functioning as measured using the Interpersonal Competence Scale (self- and collateral reports).

  9. Changes from Baseline scores compared to 16 months post-Baseline Housing Stability (measured at 0, 2, 4, 6, 8, 12 and 16 months). [ Time Frame: Baseline to 16 months. ]
    Housing stability as measured using the Time Line Follow Back (self- and collateral reports) and from archival records.

  10. Changes from Baseline scores compared to 16 months post-Baseline Relationship Closeness and Discord (measured at 0, 2, 4, 6, 8, 12 and 16 months). [ Time Frame: Baseline to 16 months. ]
    Relational closeness and relational discord as measured by the Network of Relationship Inventory (self- and collateral reports).

  11. Changes from Baseline scores compared to 16 months post-Baseline School/Employment Involvement (measured at 0, 2, 4, 6, 8, 12 and 16 months). [ Time Frame: Baseline to 16 months. ]
    Days in school or work (gainful activities) as measured using the Time Line Follow Back (self- and collateral reports) and from archival records.

  12. Changes from Baseline scores compared to 16 months post-Baseline Mental Health Symptoms (measured at 0, 2, 4, 6, 8, 12 and 16 months). [ Time Frame: Baseline to 16 months. ]
    The severity and number of mental health symptoms as measured using the Brief Symptom Inventory and the Posttraumatic Stress Disorder Checklist (self- and collateral reports).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   17 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 17 to 21 years
  • Recent arrest or release from jail/prison/detention (within the past 18 months but excluding arrest for parole/probation violations)
  • Presence of alcohol or drug (AOD) abuse disorder and recent AOD use (within the past 90 days)
  • Able to reside in a stable community setting (not currently homeless, not currently in-patient; can include individuals ready for discharge to the community)

Exclusion Criteria:

  • Actively psychotic, suicidal, or homicidal
  • Pervasive Development Disorders (PDD) or mental retardation
  • Sex offending as the primary offense type

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03035877


Contacts
Layout table for location contacts
Contact: Ashli J Sheidow, Ph.D. 541-485-2711 AshliS@oslc.org
Contact: Maryann Davis, Ph.D. 508-856-8718 Maryann.Davis@umassmed.edu

Locations
Layout table for location information
United States, Tennessee
Youth Villages Recruiting
Memphis, Tennessee, United States, 38133
Contact: Heather Thomasson    901-335-7625      
Sponsors and Collaborators
Oregon Social Learning Center
University of Massachusetts, Worcester

Layout table for additonal information
Responsible Party: Ashli Sheidow, Senior Research Scientist, Oregon Social Learning Center
ClinicalTrials.gov Identifier: NCT03035877     History of Changes
Other Study ID Numbers: 1R01DA041425-01 ( U.S. NIH Grant/Contract )
First Posted: January 30, 2017    Key Record Dates
Last Update Posted: March 13, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ashli Sheidow, Oregon Social Learning Center:
Antisocial Behavior
Alcohol Abuse
Drug Abuse
Young Adults
Additional relevant MeSH terms:
Layout table for MeSH terms
Antisocial Personality Disorder
Personality Disorders
Mental Disorders